Chemical formula: C₁₆H₁₆N₂O₃S Molecular mass: 316.375 g/mol PubChem compound: 134018
Uric acid is the end product of purine metabolism in humans and is generated in the cascade of hypoxanthine → xanthine → uric acid. Both steps in the above transformations are catalyzed by xanthine oxidase (XO). Febuxostat is a 2-arylthiazole derivative that achieves its therapeutic effect of decreasing serum uric acid by selectively inhibiting XO.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| M04AA03 | Febuxostat | M Musculo-skeletal system → M04 Antigout preparations → M04A Antigout preparations → M04AA Preparations inhibiting uric acid production |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| ULORIC Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| ADENURIC Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Febuxostat is an active ingredient of these brands:
United States (US)Albania (AL)Australia (AU)Canada (CA)Finland (FI)France (FR)Ireland (IE)Israel (IL)Italy (IT)Japan (JP)Netherlands (NL)New Zealand (NZ)Nigeria (NG)Singapore (SG)Spain (ES)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
